Pacira (PCRX) BioSciences Well-Positioned With Genicular Outcomes Registry Evidence

Pacira BioSciences Inc. (NASDAQ:PCRX) is 1 of the 7 champion small-cap cause manufacturing stocks to bargain according to hedge funds.

On March 2, Pacira BioSciences Inc. (NASDAQ:PCRX) presented information from its IGOR registry astatine the American Academy of Orthopedic Surgeons (AAOS) 2026 Annual Meeting. The institution highlighted that Exparel was associated with improved symptom outcomes, reduced opioid use, and shorter infirmary stays compared to modular treatments.

Pressmaster/Shutterstock.com

The institution besides noted that iovera demonstrated longer-lasting symptom alleviation and functional improvement, with benefits extending up to 12 months. The findings enactment the company’s increasing beingness successful post-surgical symptom absorption solutions.

On February 12, Pacira BioSciences Inc. (NASDAQ:PCRX) brought to attraction the caller survey results that person been released by the Voices for Non-Opioid Choices coalition. The results bespeak the effect to the archetypal twelvemonth of implementation of the Non-Opioids Prevent Addiction, NOPAIN, Act. This was done by conducting a nationalist consciousness campaign, trials, and usage survey of astir 750 infirmary and wellness strategy directors of pharmacy, aesculapian directors, surgeons, and anaesthesiologists wrong ambulatory country centres.

The results of this survey amusement the opening interaction of the NOPAIN Act. This enactment was implemented connected January 1, 2025, and the results concluded that 85 percent of installation representatives surveyed were alert of the legislation. In addition, much than fractional of the facilities surveyed person implemented changes to summation the utilization of qualifying non-opioid options. Over 80 percent of those surveyed person seen a simplification successful opioid prescribing for contiguous post-surgery and discharge owed to the legislation.

Pacira BioSciences Inc. (NASDAQ:PCRX) is focused connected the improvement and selling of non-opioid symptom absorption and regenerative wellness solutions to aesculapian practitioners. Its portfolio includes EXPAREL, ZILRETTA, PCRX-201, NOCITA, and a handheld cryoanalgesia device.

While we admit the imaginable of PCRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.